SCHEMBL905113

SCHEMBL905113

Cc1cc(F)ccc1-c1ccc(/N=N/c2cc(S(=O)(=O)O)c3ccccc3c2N)cn1

nearest known ligand 0.82

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ SENP2 Q9HC62 2/20 0.67
▸ SENP1 Q9P0U3 2/20 0.67
▸ SUMO2 P61956 1/20 0.67
▸ SUMO1 P63165 1/20 0.67
▸ SENP7 Q9BQF6 1/20 0.67
▸ SENP3 Q9H4L4 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18044286 1.00 SENP2 (0.67) SENP2SENP1SUMO2SUMO1SENP7
SCHEMBL29697216 1.00 SENP2 (0.67) SENP2SENP1SUMO2SUMO1SENP7
SCHEMBL14988194 0.99 SENP2 (0.66) SENP2SENP1SUMO2SUMO1SENP7
SCHEMBL14988191 0.99 SENP2 (0.66) SENP2SENP1SUMO2SUMO1SENP7
SCHEMBL15120197 0.93 SENP2 (0.61) SENP2SENP1SUMO2SUMO1SENP7
SCHEMBL29697067 0.93 SENP2 (0.61) SENP2SENP1SUMO2SUMO1SENP7
SCHEMBL18044239 0.93 SENP2 (0.61) SENP2SENP1SUMO2SUMO1SENP7
SCHEMBL14988763 0.92 SENP2 (0.60) SENP2SENP1SUMO2SUMO1SENP7
SCHEMBL14988766 0.92 SENP2 (0.60) SENP2SENP1SUMO2SUMO1SENP7
SCHEMBL17319311 0.91 SENP2 (0.69) SENP2SENP1SUMO2SUMO1SENP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250057823-A1 COMPOSITION FOR IMPROVING CARDIAC FUNCTION KYOTO UNIVERSITY (JP) 2025-02-20 — — US claimed
EP-4454648-A1 COMPOSITION FOR IMPROVING HEART FUNCTION Kyoto University (JP) 2024-10-30 — — EP claimed
US-20240216397-A1 COMPOSITION FOR AMELIORATING SKIN TISSUE ABNORMALITY KYOTO UNIVERSITY (JP) 2024-07-04 — — US claimed
US-12011438-B2 Composition for protecting cardiomyocyte KYOTO UNIVERSITY (JP) 2024-06-18 — — US claimed
EP-4331589-A1 COMPOSITION FOR AMELIORATING ABNORMALITY OF SKIN TISSUE Kyoto University (JP) 2024-03-06 — — EP claimed
US-20220401461-A1 Pharmaceutical Composition for Protecting Cartilage KYOTO UNIVERSITY (JP) 2022-12-22 — — US claimed
EP-4049724-A1 PHARMACEUTICAL COMPOSITION FOR PROTECTING CARTILAGE Kyoto University (JP) 2022-08-31 — — EP claimed
EP-3733177-B1 COMPOSITION FOR PROTECTING CORNEA UNIV KYOTO (JP) 2022-07-06 — — EP claimed
EP-3848029-A1 MEDICINE COMPOSITION FOR TREATING CEREBRAL INFARCTION Kyoto University (JP) 2021-07-14 — — EP claimed
US-20210145808-A1 Composition for Protecting Cardiomyocyte KYOTO UNIVERSITY (JP) 2021-05-20 — — US claimed
US-20210059995-A1 Composition for Protecting Cornea KYOTO UNIVERSITY (JP) 2021-03-04 — — US claimed
EP-3782623-A1 PHARMACEUTICAL COMPOSITION FOR PROTECTING MYOCARDIAL CELLS Kyoto University (JP) 2021-02-24 — — EP claimed
EP-3733177-A1 COMPOSITION FOR CORNEAL PROTECTION Kyoto University (JP) 2020-11-04 — — EP claimed
EP-3042658-B1 MEDICINAL COMPOSITION IMPROVING LEPTIN RESISTANCE UNIV KYOTO (JP) 2019-01-16 — — EP claimed
EP-2959903-B1 MEDICINE FOR TREATING EYE DISEASE UNIV KYOTO (JP) 2018-10-03 — — EP claimed
US-9931351-B2 Method for improving leptin resistance KYOTO UNIVERSITY (JP) 2018-04-03 — — US claimed
US-9782420-B2 Method for treating eye diseases KYOTO UNIVERSITY (JP) 2017-10-10 — — US claimed
US-9573887-B2 Naphthalene derivative DAITO CHEMIX CORPORATION (JP) 2017-02-21 — — US claimed
US-20160303144-A1 Medicinal Composition Improving Leptin Resistance KYOTO UNIVERSITY (JP) 2016-10-20 — — US claimed
EP-2599771-B1 NAPHTHALENE DERIVATIVE DAITO CHEMIX CORP (JP) 2016-09-14 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250057823-A1 COMPOSITION FOR IMPROVING CARDIAC FUNCTION TNNI3, NPPA, TNNT2 SENP2 3538/4885SENP1 2852/4885SUMO2 4148/4885
US-12011438-B2 Composition for protecting cardiomyocyte TNNI3, TNNT2, TNNC1 SENP2 2730/4885SENP1 1865/4885SUMO2 2295/4885
US-20160303144-A1 Medicinal Composition Improving Leptin Resistance LIPC, ADIPOR1, GPR119 SENP2 3218/4885SENP1 3152/4885SUMO2 4540/4885
US-20210145808-A1 Composition for Protecting Cardiomyocyte TNNI3, TNNT2, TNNC1 SENP2 2730/4885SENP1 1865/4885SUMO2 2295/4885
US-20220401461-A1 Pharmaceutical Composition for Protecting Cartilage COL2A1, MATR3, COL1A1 SENP2 2405/4885SENP1 1400/4885SUMO2 2757/4885
US-20210059995-A1 Composition for Protecting Cornea VCL, VASP, VCP SENP2 1122/4885SENP1 555/4885SUMO2 1484/4885
US-20240216397-A1 COMPOSITION FOR AMELIORATING SKIN TISSUE ABNORMALITY CUTA, FABP4, MMP13 SENP2 3876/4885SENP1 3680/4885SUMO2 3580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback